Skip to main
MNOV
MNOV logo

MediciNova (MNOV) Stock Forecast & Price Target

MediciNova (MNOV) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MediciNova Inc. is strategically positioned to enhance its market presence through the advanced development of its therapeutics, particularly MN-001 and MN-002, which demonstrate potential applications across a spectrum of metabolic and cardiovascular diseases. The firm has successfully completed patient enrollment for the pivotal COMBAT-ALS Phase 3 study of MN-166, bolstering its neurology portfolio and suggesting strong future prospects in the treatment of neurological disorders. Additionally, the anticipated topline data for MN-001 in summer 2026 is expected to be a critical milestone, consolidating MediciNova’s innovative approach in addressing significant unmet medical needs.

Bears say

MediciNova Inc. faces significant challenges due to its limited product portfolio and reliance on the success of a few therapeutic candidates, which raises concerns about revenue generation and market competitiveness. The company’s financial reports indicate escalating research and development expenses without a corresponding increase in revenue, further straining its cash flow and sustainability. Additionally, the absence of diversified offerings in a competitive biopharmaceutical market may hinder its long-term growth potential and ability to attract investment.

MediciNova (MNOV) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MediciNova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MediciNova (MNOV) Forecast

Analysts have given MediciNova (MNOV) a Strong Buy based on their latest research and market trends.

According to 2 analysts, MediciNova (MNOV) has a Strong Buy consensus rating as of Dec 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MediciNova (MNOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.